BioSante plans new trials despite LibiGel's failure to perform
This article was originally published in Scrip
Executive Summary
BioSante Pharmaceuticals is pursuing development of its female sexual dysfunction drug LibiGel (testosterone gel) despite the product failing to show it was any better than placebo in treating hypoactive sexual desire disorder in postmenopausal women in two Phase III trials, BLOOM1 and BLOOM2, last year.